Posts by: Janet Stewart, MSc

Janet Stewart, MSc

Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.

June 26, 2018

Venclexta-Rituxan Combo Extends Undetectable Disease in CLL, Study Finds

News

A combination of Venclexta (venetoclax) plus Rituxan (rituximab) was better than standard of care at extending the duration of undetectable residual disease in patients with relapsed or refractory chronic lymphocytic ... Read more

February 14, 2018February 14, 2018

Mouse Study Offers New Approach to Combat Side Effect of Stem Cell Transplants, GVHD

News

A new study identified a target protein called JAK2 (Janus kinase 2) as a main player in causing graft-versus-host disease, a potential life-threatening side effect of stem cell transplants that ... Read more

January 10, 2018January 10, 2018

Breast Implants Associated with Small Increased Risk of Anaplastic Large-cell Lymphoma

News

A study found that one in 6,920 women with breast implants will develop anaplastic large-cell lymphoma (ALCL) in the breast before they reach the age of 75. Even though the ... Read more

December 14, 2017December 14, 2017

5-Year Survival Rates Promising for MTLC Patients Treated with Adcetris in Phase 1 Trial

News

Seattle Genetics reported promising five-year survival results from its Phase 1 clinical trial of Adcetris (brentuximab vedotin) in mature T-cell lymphoma (MTCL), also known as peripheral T-cell lymphoma. The findings ... Read more

November 27, 2017November 27, 2017

3D Imaging of Hodgkin Lymphoma May Help Predict Survival Outcomes, Study Finds

News

A new 3D imaging approach for patients with early-stage Hodgkin lymphoma (HL) was better at predicting survival outcomes than standard two-dimensional imaging, a study has found. Also, early-stage unfavorable HL ... Read more

November 13, 2017November 13, 2017

FDA Approves Adcetris for Most Common Subtypes of Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Seattle Genetics’ Adcetris (brentuximab vedotin) for the treatment of adults with the two most common subtypes of cutaneous T-cell lymphoma (CTCL) — ... Read more

November 6, 2017

Bayer to Present Long-term Results of Aliqopa in Treating Indolent Lymphomas at ASH 2017

News

Bayer will present long-term safety and efficacy data from the CHRONOS-1 trial of Aliqopa (copanlisib) in patients with indolent lymphomas at the American Society of Hematology (ASH) 2017 Annual Meeting ... Read more

October 31, 2017

Health Canada OKs Imbruvica for Treating Chronic Graft-Versus-Host Disease

News

Janssen‘s Imbruvica (ibrutinib) has been approved by Health Canada for treating chronic graft-versus-host disease (cGVHD), a life-threatening condition that some patients develop after a stem cell transplant. Following a priority ... Read more

October 16, 2017October 16, 2017

Remetinostat’s Promising Results in Mycosis Fungoides Patients Presented at EORTC Meeting

News

Topical remetinostat 1% gel can significantly reduce the severity of skin lesions and itching in mycosis fungoides (MF) patients without systemic adverse events, data from a Phase 2 trial show. The ... Read more

October 9, 2017

Adcetris Induced Durable, Long-term Remission in Nearly Half of Large Cell Lymphoma Patients in Phase 2 Trial

News

More than half of patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL, a particularly aggressive type of lymphoma) who received Adcetris (brentuximab vedotin) during a pivotal Phase 2 ... Read more